Bowlby Deborah A, Rapaport Robert
Kravis Children's Hospital at Mount Sinai, Division of Pediatric Endocrinology and Diabetes, New York, NY 10029, USA.
Pediatr Endocrinol Rev. 2004 Nov;2 Suppl 1:68-77.
Growth hormone (GH) has been used for more than 40 years. GH improves height velocity in many conditions associated with impaired growth and corrects metabolic deficits attributable to GH deficiency (GHD). Many studies and surveillance programs exist to collect efficacy and safety data. GH has been demonstrated to have a relatively wide safety margin. Reported side effects, including pseudotumor cerebri, edema, slipped capital femoral epiphysis (SCFE), worsening of scoliosis, gynecomastia, and hyperglycemia require careful monitoring. Currently, there are no data suggesting that GH therapy increases the risk of developing de novo, recurrent, or secondary malignancies. Patients who have a high intrinsic risk factor for the development of an adverse event need more vigilant surveillance.
生长激素（GH）已使用40多年。在许多与生长受损相关的情况下，GH可提高身高增长速度，并纠正因生长激素缺乏症（GHD）导致的代谢缺陷。有许多研究和监测项目来收集疗效和安全性数据。已证明GH具有相对较宽的安全范围。报告的副作用包括假性脑瘤、水肿、股骨头骨骺滑脱（SCFE）、脊柱侧弯加重、男性乳房发育和高血糖，需要仔细监测。目前，没有数据表明GH治疗会增加新发、复发或继发性恶性肿瘤的发生风险。具有发生不良事件高内在风险因素的患者需要更密切的监测。
